查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830965

连续性肾臟替代疗法市场

Continuous Renal Replacement Therapy Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

连续性肾臟替代疗法市场预计将从 2024 年的 16.7 亿美元扩大到 2031 年的 29.8 亿美元。预计该市场在 2025 年至 2031 年期间的复合年增长率将达到 8.7%。市场洞察与分析师观点：本报告概述了基于连续性肾臟替代疗法市场当前趋势的成长机会及其在预测期内的预期影响。

连续性肾臟替代疗法 (CRRT) 是重度急性肾损伤 (AKI)、液体超负荷和尿毒症患者的关键治疗方法，这些疾病可能导致危及生命的代谢紊乱。儿科 CRRT 设备需求的不断增长以及导致肾臟疾病的慢性疾病的高发病率，正在推动连续性肾臟替代疗法市场的成长。然而，重大不良肾臟事件 (MAKE) 的高风险对市场扩张构成了挑战。

市场驱动因素：导致肾臟疾病的慢性病高发生率全球每 10 人中就有 1 人患有慢性肾病 (CKD)，这是一种普遍且可能致命的疾病。 2015 年至 2019 年间，75% 的肾衰竭病例是由糖尿病和高血压引起的。根据美国国家肾臟基金会 2020 年的估计，美国 20 岁以上的糖尿病患者中约有 30% 在其一生中面临 CKD 的风险。此外，2020 年 CKD 造成的死亡人数超过了前列腺癌或乳腺癌，突显了其作为一种未被充分认识的紧急卫生状况。大约三分之一的美国成年人（约 8,000 万人）面临 CKD 的风险，CKD 现在被认为是 AKI 的重要危险因子。肾小球滤过率 (GFR) 降低和蛋白尿增加与 AKI 密切相关。

美国国立卫生研究院 (NIH) 报告称，已开发国家急性肾损伤 (AKI) 的发生率正在上升，预计住院患者的盛行率将达到 15%，重症患者的盛行率甚至更高，达到 60%。全球住院病患的 AKI 发生率为 0.7% 至 31%，ICU 病患的盛行率则超过 50%。 3% 至 13% 的 AKI 患者需要肾臟替代疗法 (RRT)，其中 40% 的患者估计需要接受 CRRT 治疗超过 90 天。因此，导致肾臟疾病的慢性疾病的高盛行率显着促进了持续性肾臟替代疗法市场的成长。

然而，连续性肾臟替代疗法 (CRRT) 存在一些副作用，例如低血压、心搏过速和其他心律不整，这些副作用可能会对患者病情产生负面影响或阻碍復原。此外，CRRT 循环可能导致微量营养素、微量元素和/或治疗药物的快速清除，导致血液和组织中药物浓度降低或不一致，从而引起副作用或降低治疗效果。因此，这些副作用限制了连续性肾臟替代疗法 (CRRT) 市场的成长。

策略洞察报告细分和范围：透过检查以下细分市场对连续性肾臟替代疗法市场进行分析：产品、方式和最终用户。

細項分析：持续性肾臟替代疗法 (CRRT) 市场按产品分为透析液和置换液、一次性用品、血路套件和导管、CRRT 系统以及血液滤器。 CRRT 系统细分市场在 2022 年占据最大市场份额，而血液滤网细分市场预计在 2022 年至 2030 年期间的复合年增长率最高。

依治疗方式划分，连续性肾臟替代疗法市场分为连续性静脉-静脉血液滤过 (CVVH)、连续性静脉-静脉血液透析滤过 (CVVHDF)、连续性静脉-静脉血液透析 (CVVHD) 和慢速连续超滤 (SCUF)。 CVVH 细分市场在 2022 年占据最大市场份额，而 CVVHDF 细分市场预计将在 2022-2030 年期间实现最高复合年增长率。

按最终用户划分，持续性肾臟替代治疗市场可细分为医院、门诊护理中心、家庭护理和其他。 2022年，医院护理领域占据主导地位，但预计家庭监护领域在2022年至2030年期间的复合年增长率最高。

区域分析：连续性肾臟替代治疗市场报告涵盖北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国、印度、日本、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地区）。

就收入而言，北美在2022年引领了连续性肾臟替代疗法市场。预计亚太市场将在2022年至2030年期间实现最高的复合年增长率，这得益于医疗基础设施的改善和创新连续性肾臟替代治疗（CRRT）技术的采用，而这些因素与医疗支出的成长息息相关。此外，市场参与者为提升其在亚太地区的影响力而采取的策略性倡议，例如与当地医疗机构建立合作伙伴关係，也支持了该地区市场的成长。

连续性肾臟替代疗法市场报告范围、竞争格局和主要公司：连续性肾臟替代疗法市场报告重点关注百特国际公司、旭化成、费森尤斯医疗、Medica SpA、美敦力公司、贝朗、日机装株式会社、东丽医疗株式会社、Infomed SA 和 Quanta Dialysis Technologies Inc. 等主要参与者。连续性肾臟替代疗法市场的预测可以帮助利害关係人规划其成长策略。这些公司正专注于推出新技术、改进现有产品并扩展业务，以满足日益增长的全球消费者需求。

2022年4月，美国食品药物管理局 (FDA) 批准百特国际公司 (Baxter International Inc.) 生产的 ST Set 用于连续性肾臟替代疗法 (CRRT)。 ST Set 是一种预先连接的一次性体外循环迴路，透过半透膜进行血液净化，设计用于 PrisMax 或 Prismaflex 控制装置（监视器）。 2022年3月，领先的肾臟、血管和外科医疗产品製造商和供应商 Nipro Medical Corporation (Nipro) 宣布在美国推出 SURDIAL DX 血液透析系统。 SURDIAL DX 是一款先进的血液透析系统，旨在为患者和临床医生提供最佳的透析治疗体验。该产品在日本製造，基于 Nipro 母公司 Nipro Corporation 超过 35 年的肾臟设备创新专业知识。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：连续性肾臟替代疗法市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：连续性肾臟替代疗法市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：连续性肾臟替代疗法市场－全球市场分析

  • 连续性肾臟替代疗法—全球市场概览
  • 连续性肾臟替代疗法－全球市场及2030年预测

第七章：连续性肾臟替代疗法市场 - 收入分析 - 按产品，2020-2030 年

  • 概述
  • 透析液和置换液
  • 免洗用品
  • 血统套装和试管
  • 血液滤器
  • CRRT系统

第 8 章：连续性肾臟替代疗法市场 - 收入分析 - 按治疗方式，2020-2030 年

  • 概述
  • 持续性静脉-静脉血液滤过（CVVH）
  • 持续性静脉-静脉血液透析滤过（CVVHDF）
  • 持续性静脉-静脉血液透析（CVVHD）
  • 慢速连续超滤（SCUF）

第九章：连续性肾臟替代疗法市场-收入分析-按最终用户，2020-2030

  • 概述
  • 医院
  • 门诊护理
  • 居家护理
  • 其他的

第 10 章：连续性肾臟替代疗法市场 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 东南亚其他地区
  • 中东和非洲
    • 南非
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：连续性肾臟替代疗法市场 - 主要公司简介

  • Baxter International Inc
  • Asahi Kasei
  • Fresenius Medical Care
  • Medica S.p.A.
  • Medtronic Plc
  • B. Braun
  • Nikkiso Co Ltd
  • Toray Medical Co Ltd
  • Infomed SA
  • Quanta Dialysis Technologies Inc

第 14 章：附录

简介目录
Product Code: TIPHE100001251

The continuous renal replacement therapy market is expected to expand from US$ 1.67 billion in 2024 to US$ 2.98 billion by 2031. The market is projected to achieve a CAGR of 8.7% from 2025 to 2031.

Market Insights and Analyst View:This report outlines growth opportunities based on the current trends in the continuous renal replacement therapy market and their anticipated effects during the forecast period.

Continuous renal replacement therapy (CRRT) is a critical treatment for patients experiencing severe acute kidney injury (AKI), fluid overload, and uremia, which can lead to life-threatening metabolic disturbances. The rising demand for pediatric CRRT devices and the high incidence of chronic diseases that result in kidney disorders are driving the growth of the continuous renal replacement therapy market. However, the significant risk of major adverse kidney events (MAKE) poses a challenge to market expansion.

Market Drivers:High Prevalence of Chronic Diseases Leading to Kidney Disorders

Globally, 1 in 10 individuals is affected by chronic kidney disease (CKD), a prevalent and potentially fatal condition. Between 2015 and 2019, diabetes and hypertension were responsible for 75% of kidney failure cases. According to the National Kidney Foundation's 2020 estimates, approximately 30% of the diabetic population over 20 years old in the US is at risk of developing CKD during their lifetime. Furthermore, CKD caused more fatalities than prostate or breast cancer in 2020, highlighting its status as an under-recognized health emergency. About 1 in 3 American adults (around 80 million people) are at risk of CKD, which is now recognized as a significant risk factor for AKI. A decreased glomerular filtration rate (GFR) and increased proteinuria are closely linked to AKI.

The National Institute of Health reports a rising incidence of AKI in developed nations, with its prevalence among hospitalized patients expected to reach 15%, and even higher in critically ill patients at 60%. The global incidence of AKI in hospitalized patients ranges from 0.7% to 31%, with ICU patients experiencing rates exceeding 50%. Between 3% and 13% of AKI patients require renal replacement therapy (RRT), and 40% of these patients are estimated to need CRRT for over 90 days. Thus, the high prevalence of chronic diseases leading to kidney disorders significantly enhances the growth of the continuous renal replacement therapy market.

However, CRRT is associated with adverse effects such as hypotension, tachycardia, and other arrhythmias, which can negatively impact patient conditions or hinder recovery. Additionally, the CRRT circuit may lead to the rapid clearance of micronutrients, trace elements, and/or therapeutic drugs, resulting in low or inconsistent concentrations in blood and tissues, which can cause adverse effects or diminish therapeutic efficacy. Consequently, these adverse effects limit the growth of the continuous renal replacement therapy market.

Strategic Insights

Report Segmentation and Scope:The analysis of the continuous renal replacement therapy market has been conducted by examining the following segments: product, modality, and end user.

Segmental Analysis:The continuous renal replacement therapy market is categorized by product into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest market share in 2022, while the hemofilters segment is expected to exhibit the highest CAGR from 2022 to 2030.

By modality, the continuous renal replacement therapy market is divided into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The CVVH segment accounted for the largest market share in 2022, with the CVVHDF segment anticipated to achieve the highest CAGR during 2022-2030.

By end user, the continuous renal replacement therapy market is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the market share, but the home monitoring segment is projected to register the highest CAGR from 2022 to 2030.

Regional Analysis:The continuous renal replacement therapy market report covers North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue, North America led the continuous renal replacement therapy market in 2022. The Asia Pacific market is expected to register the highest CAGR from 2022 to 2030, driven by improvements in healthcare infrastructure and the adoption of innovative CRRT technologies, which are linked to increasing healthcare expenditures. Additionally, strategic initiatives by market players to enhance their presence in the Asia Pacific region, such as partnerships with local healthcare providers, support market growth in this area.

Continuous Renal Replacement Therapy Market Report Scope

Competitive Landscape and Key Companies:The continuous renal replacement therapy market report focuses on key players such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. The forecast for the continuous renal replacement therapy market can assist stakeholders in planning their growth strategies. These companies are concentrating on launching new technologies, enhancing existing products, and expanding their operations to meet the increasing global consumer demand.

In April 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance for the ST Set by Baxter International Inc. for use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal circuit that facilitates blood purification through a semipermeable membrane, designed for use with the PrisMax or Prismaflex control units (monitors).

In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. The SURDIAL DX is a cutting-edge hemodialysis system aimed at providing an optimal dialysis treatment experience for both patients and clinicians. Manufactured in Japan, this product is based on over 35 years of expertise in renal device innovation from Nipro's parent company, Nipro Corporation.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Continuous Renal Replacement Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Continuous Renal Replacement Therapy Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Continuous Renal Replacement Therapy Market - Global Market Analysis

  • 6.1 Continuous Renal Replacement Therapy - Global Market Overview
  • 6.2 Continuous Renal Replacement Therapy - Global Market and Forecast to 2030

7. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Dialysates and Replacement Fluids
  • 7.3 Disposables
  • 7.4 Bloodline Sets and Tubes
  • 7.5 Hemofilters
  • 7.6 CRRT Systems

8. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By Modality, 2020-2030

  • 8.1 Overview
  • 8.2 Continuous venovenous hemofiltration (CVVH)
  • 8.3 Continuous venovenous hemodiafiltration (CVVHDF)
  • 8.4 Continuous venovenous hemodialysis (CVVHD)
  • 8.5 Slow continuous ultrafiltration (SCUF)

9. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital
  • 9.3 Ambulatory care
  • 9.4 Homecare
  • 9.5 Others

10. Continuous Renal Replacement Therapy Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Continuous Renal Replacement Therapy Market Overview
    • 10.1.2 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts to 2030
    • 10.1.3 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Modality
    • 10.1.5 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Continuous Renal Replacement Therapy Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Continuous Renal Replacement Therapy Market
        • 10.1.6.1.1 United States Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.1.2 United States Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.1.3 United States Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.2 Canada Continuous Renal Replacement Therapy Market
        • 10.1.6.2.1 Canada Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.2.2 Canada Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.2.3 Canada Continuous Renal Replacement Therapy Market, by End User
      • 10.1.6.3 Mexico Continuous Renal Replacement Therapy Market
        • 10.1.6.3.1 Mexico Continuous Renal Replacement Therapy Market, by Product
        • 10.1.6.3.2 Mexico Continuous Renal Replacement Therapy Market, by Modality
        • 10.1.6.3.3 Mexico Continuous Renal Replacement Therapy Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of SouthEast Asia
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 U.A.E
    • 10.4.3 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Continuous Renal Replacement Therapy Market - Key Company Profiles

  • 13.1 Baxter International Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Asahi Kasei
  • 13.3 Fresenius Medical Care
  • 13.4 Medica S.p.A.
  • 13.5 Medtronic Plc
  • 13.6 B. Braun
  • 13.7 Nikkiso Co Ltd
  • 13.8 Toray Medical Co Ltd
  • 13.9 Infomed SA
  • 13.10 Quanta Dialysis Technologies Inc

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud